&NA;Lerisetron (F 0930RS, F 0930) is a serotonin 5-HT3receptor antagonist with potential as an antiemetic agent. Lerisetron is currently undergoing phase II trials with FAES in Spain. With the exception of Spain and Portugal, lerisetron is available for licensing worldwide.